Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label multicenter study of relugolix tablets in androgen-sensitive progressive prostate cancer
CTR20253072Phase 3Active
- Sponsor
- Jiangsu Lianhuan Pharmaceutical Co., Ltd.
- Start
- Oct 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tissue-plasminogen activator in prostate adenocarcinoma and prostate cancer (PCa) (2 arms), sponsored by Jiangsu Lianhuan Pharmaceutical Co., Ltd. Primary endpoint: Sustained castration rate of serum testosterone. Started Oct 2025; status: active.
02
Drugs
tissue-plasminogen activator
03
Conditions
prostate adenocarcinomaprostate cancer (PCa)
Beyond the preview
Go deeper on CTR20253072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253072.